You are here: Industry Insights > Halozyme

News List

Collaboration to develop ultra-long acting medicines for HIV europeanpharmaceuticalreview
June 23, 2021
ViiV Healthcare is licencing Halozyme’s Enhanze® drug delivery technology to help develop ultra-long acting versions of its long-acting HIV pipeline products.
Janssen Submits Light Chain Amyloidosis Treatment to FDA americanpharmaceuticalreview
September 17, 2020
Halozyme Therapeutics announced its collaborator Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) ...
Halozyme Announces FDA Accepted BLA for Fixed-Dose Subcutaneous Perjeta, Herceptin Combination americanpharmaceuticalreview
March 05, 2020
Halozyme Therapeutics announced the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech ...
Halozyme Announces argenx Has Selected Second Target under ENHANZE® Technology Collaboration, License Agreement americanpharmaceuticalreview
May 23, 2019
Halozyme Therapeutics announced argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.
Halozyme licenses $25M drug delivery technology to Roche biospectrumasia
November 26, 2018
Halozyme has out-licensed its ENHANZE drug delivery technology to Roche for the exclusive development of a new undisclosed drug target with an option to add two more within four years.
Roche taps Halozyme’s drug delivery tech for up to $520M fiercebiotech
November 02, 2018
Roche and Halozyme are at it again—12 years after their initial collaboration around the latter’s Enhanze drug delivery platform, Roche is licensing it again, this time...
Halozyme Announces New Board of Directors Appointment americanpharmaceuticalreview
September 11, 2018
Halozyme Therapeutics announced the appointment of Bernadette Connaughton to its board of directors. Connaughton brings more than 30 years of global strategic, commercial and biopharmaceutical industry expertise to the board.
Halozyme Provides Update on SWOG Collaborative Group Clinical Study americanpharmaceuticalreview
March 31, 2017
Halozyme Therapeutics announced it has been informed by SWOG that the SWOG Phase 1b/2 trial evaluating PEGPH20 plus modified FOLFIRINOX chemotherapy versus modified FOLFIRINOX alone in patients with previously untreated metastatic pancreas cancer has been
Halozyme Announces Phase 2 Study in Advanced Pancreas Cancer Meets Key Endpoints americanpharmaceuticalreview
January 06, 2017
Halozyme Therapeutics has reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study, a Phase 2 randomized, multi-center clinical trial of lead investigational drug PEGPH20 in combination with ABRAXANE® (